The numbers of Americans living with HIV who are aged over 65 is projected to grow rapidly over the next decade and will result in large numbers of patients who have multiple co-morbidities in addition to HIV, Dr Parastu Kasaie of Johns Hopkins University told the virtual Conference on Retroviruses and Opportunistic Infections (CROI 2021)… Read More »
A US study has concluded that weight gain is greater by around 2 to 4 kg in HIV-positive people taking bictegravir or dolutegravir as part of their first antiretroviral therapy (ART), compared to their counterparts using other drug regimens. A similar effect was reported in those using the protease inhibitor darunavir. The study led by… Read More »
FDA Approves Veklury (remdesivir) for the Treatment of COVID-19 FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 22, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication… Read More »
COPD is one of the leading causes of morbidity and mortality[1]. Living with chronic pulmonary obstructive disease (COPD) is often challenging now and then. Your lifestyle will inevitably change after being diagnosed with COPD. Unfortunately, it is not going to be be easy to lead a normal life as COPD progression appears. COPD symptoms are… Read More »
PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »